Our website uses cookies to improve and personalise your experience and to display advertisements(if any). Our website may also include third-party cookies like Google Adsense, Google Analytics, and Youtube. By using the website, you consent to the use of cookies. We have updated our Privacy Policy. Please click on the button to check our Privacy Policy.

New vaccine plant in Senegal gets 75 million euros from EIB

THE European Investment Bank (EIB) committed 75 million euros ($80 million) to finance the construction of a new facility in Senegal that will produce COVID-19 and other vaccines for use across Africa.

The plant, run by the Dakar-based Institut Pasteur, is intended to help Africa reduce its dependence on vaccine imports, which currently account for 99% of the continent’s needs. It will produce vaccines against COVID-19, yellow fever and other endemic diseases.

The EIB and the European Union had already donated 5 million euros in 2021 for feasibility studies and project preparation for the plant.

Institut Pasteur hopes the facility will begin producing vaccines before the end of the year. At full capacity, it should produce up to 300 million vaccine doses per year, the EIB said in a statement announcing the new financing.

Africa’s reliance on outside manufacturing delayed the rollout of COVID vaccines last year. Doses have since arrived in force, but inoculation rates remain low in many countries due to logistical challenges and vaccine hesitancy.

“It is essential to create decentralised vaccine manufacturing capacity to address this imbalance and ultimately build a safer and healthier world,” said Amadou Alpha Sall, Institut Pasteur’s director in Senegal.

The institute in the capital Dakar is jointly run by the Senegalese government and the Paris-based Institut Pasteur.

“Since the beginning of the coronavirus pandemic, we have maintained that no one is safe until everyone is safe,” said Irene Mingasson, the head of the EU delegation to Senegal.

There have been several initiatives during the pandemic to boost vaccine manufacturing in Africa, but some have struggled.

South Africa’s Aspen Pharmacare said last month it might slash its capacity to package and sell the COVID vaccine made by Johnson & Johnson after receiving no orders.